Biomea Fusion Inc (BMEA) is not a strong buy at this moment for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of significant trading trends, and no recent positive news or catalysts make this stock less attractive. While the technical indicators show some positive momentum, they are not strong enough to outweigh the negative financial performance and lack of growth. For now, holding off on this investment is advisable.

Technical Analysis

The MACD histogram is positive and expanding, indicating upward momentum. RSI is in the neutral zone at 75.133, suggesting no overbought or oversold conditions. Moving averages are converging, and the stock is trading near its resistance levels (R1: 1.419, R2: 1.479). However, the pre-market and post-market price changes show slight downward pressure.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low Put-Call Ratios suggest bullish sentiment in the options market. However, the overall trading volume is low, and implied volatility is high at 102.76, indicating potential price swings.

Technical Summary

Sell

Buy

Positive Catalysts

The MACD and options sentiment suggest some short-term bullish momentum.

Neutral/Negative Catalysts

No recent news, poor financial performance in Q3 2025 (Net Income dropped by -49.96% YoY, EPS dropped by -70.33% YoY), no significant insider or hedge fund activity, and no recent congress trading data.

Financial Performance

In Q3 2025, the company showed no revenue growth (0% YoY), a significant drop in Net Income (-49.96% YoY), and a sharp decline in EPS (-70.33% YoY). Gross Margin remained at 0%. Overall, the financial performance is weak and does not support a strong buy recommendation.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available on analyst ratings or price target changes.

5 Analyst Rating

Wall Street analysts forecast BMEA stock price to rise

4 Buy

0 Hold

1 Sell

Moderate Buy

Current: 1.370

Low

Averages

7.75

High

Current: 1.370

Low

Averages

7.75

High

JPMorgan

Neutral -> Underweight

downgrade

AI Analysis

2025-11-15

Reason

JPMorgan

Price Target

AI Analysis

2025-11-15

downgrade

Neutral -> Underweight

Reason

JPMorgan downgraded Biomea Fusion to Underweight from Neutral without a price target. The firm views the recent phase 2 COVALENT II icovamenib data in type 2 diabetes as "interesting" but has concerns around the company's ability to fund the ongoing and planned studies. The funding may come with significant dilution over the long-term without a partnership, which is difficult to predict, the analyst tells investors in a research note.

Citi

Buy

downgrade

$7 -> $6

2025-11-10

Reason

Citi

Price Target

$7 -> $6

2025-11-10

downgrade

Buy

Reason

Citi lowered the firm's price target on Biomea Fusion to $6 from $7 and keeps a Buy rating on the shares following the Q3 report. The firm cites the company's higher spending and dilution from the recent public offering for the target drop.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BMEA

Unlock Now

BMEA Should I Buy

BMEA Should I Buy

Should You Buy Biomea Fusion Inc (BMEA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch